Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Bedaquiline: First FDA-approved tuberculosis drug in 40 years.

Mahajan R.

Int J Appl Basic Med Res. 2013 Jan;3(1):1-2. doi: 10.4103/2229-516X.112228. No abstract available.

2.

Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.

Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12. Erratum in: MMWR Recomm Rep. 2013 Nov 15;62(45):906.

3.

Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.

Kakkar AK, Dahiya N.

Tuberculosis (Edinb). 2014 Jul;94(4):357-62. doi: 10.1016/j.tube.2014.04.001. Epub 2014 Apr 18. Review.

PMID:
24841672
4.

[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].

Monneret C.

Ann Pharm Fr. 2014 Jul;72(4):229-37. doi: 10.1016/j.pharma.2014.03.001. Epub 2014 May 6. Review. French.

PMID:
24997884
5.

Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.

Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.

Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15.

PMID:
25320286
6.

A review of tuberculosis: Focus on bedaquiline.

Chan B, Khadem TM, Brown J.

Am J Health Syst Pharm. 2013 Nov 15;70(22):1984-94. doi: 10.2146/ajhp130199. Review.

PMID:
24173008
7.

Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.

Chahine EB, Karaoui LR, Mansour H.

Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1. Review.

PMID:
24259600
8.

Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue.

Qiao CJ, Wang XK, Xie F, Zhong W, Li S.

Molecules. 2015 Dec 11;20(12):22272-85. doi: 10.3390/molecules201219846.

9.

Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.

Gupta S, Tyagi S, Bishai WR.

Antimicrob Agents Chemother. 2015 Jan;59(1):673-6. doi: 10.1128/AAC.04019-14. Epub 2014 Oct 20.

10.

Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.

Worley MV, Estrada SJ.

Pharmacotherapy. 2014 Nov;34(11):1187-97. doi: 10.1002/phar.1482. Epub 2014 Sep 9. Review.

PMID:
25203970
11.

Rising to the challenge: new therapies for tuberculosis.

Wong EB, Cohen KA, Bishai WR.

Trends Microbiol. 2013 Sep;21(9):493-501. doi: 10.1016/j.tim.2013.05.002. Epub 2013 Jun 11. Review.

12.

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.

Svensson EM, Murray S, Karlsson MO, Dooley KE.

J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.

13.

Bedaquiline metabolism: enzymes and novel metabolites.

Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X.

Drug Metab Dispos. 2014 May;42(5):863-6. doi: 10.1124/dmd.113.056119. Epub 2014 Feb 10.

14.

Bedaquiline. More data needed on this dangerous antitubercular drug.

[No authors listed]

Prescrire Int. 2014 Oct;23(153):232-4.

PMID:
25964964
15.

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

van Heeswijk RP, Dannemann B, Hoetelmans RM.

J Antimicrob Chemother. 2014 Sep;69(9):2310-8. doi: 10.1093/jac/dku171. Epub 2014 May 23. Review.

PMID:
24860154
16.

Bedaquiline for the treatment of drug-resistant tuberculosis.

Bélard S, Heuvelings CC, Janssen S, Grobusch MP.

Expert Rev Anti Infect Ther. 2015 May;13(5):535-53. doi: 10.1586/14787210.2015.1021785. Epub 2015 Mar 22. Review.

PMID:
25797824
17.

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK.

Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0. Epub 2012 Jul 23.

PMID:
22828481
18.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group.

N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.

19.

Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207).

Grosset JH, Ammerman NC.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):649-51. doi: 10.1586/14787210.2013.811848.

PMID:
23879605
20.

Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.

Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW.

Clin Ther. 2016 Mar;38(3):655-67.e1-2. doi: 10.1016/j.clinthera.2016.01.023. Epub 2016 Feb 20.

PMID:
26907504

Supplemental Content

Support Center